Detection of CJC‐1295 in Equine Plasma by ELISA

Mark Timms, Adam Cawley, Rohan Steel
Drug Testing and Analysis · Wiley · 2026-10-15 · DOI: 10.1002/dta.70171

Abstract

ABSTRACT CJC‐1295 is a peptide‐based drug that stimulates the endogenous production of growth hormone (GH). Compared to other growth hormone releasing hormone (GHRH) analogues, CJC‐1295 has an extended half‐life due to a drug affinity complex (DAC) that chemically crosslinks the peptide to plasma proteins containing free cysteine residues. As a result, CJC‐1295 behaves more like a protein doping agent than a typical peptide‐based drug. Using monoclonal antibodies raised against the CJC‐1295 peptide, an ELISA was developed for the detection of CJC‐1295 protein conjugates in equine plasma at concentrations as low as 12.5 pg/mL. The effectiveness of the assay for controlling the illicit use of CJC‐1295 was demonstrated using equine blood samples, obtained from thoroughbred racehorses, following subcutaneous administration of 10 mg of CJC‐1295.

Read at publisher →

Similar articles